Casdin Capital’s BioLife Solutions BLFS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $131M | Sell |
4,655,000
-1,302,165
| -22% | -$30.4M | 6.58% | 4 |
|
|
2026
Q1 | $114M | Hold |
5,957,165
| – | – | 8.61% | 4 |
|
|
2025
Q4 | $144M | Sell |
5,957,165
-750,000
| -11% | -$19.6M | 8.95% | 3 |
|
|
2025
Q3 | $171M | Sell |
6,707,165
-1,000,000
| -13% | -$23.7M | 14.27% | 2 |
|
|
2025
Q2 | $166M | Sell |
7,707,165
-1,000,000
| -11% | -$22.5M | 15.12% | 2 |
|
|
2025
Q1 | $199M | Hold |
8,707,165
| – | – | 16.25% | 2 |
|
|
2024
Q4 | $226M | Hold |
8,707,165
| – | – | 15.04% | 2 |
|
|
2024
Q3 | $218M | Hold |
8,707,165
| – | – | 14.54% | 1 |
|
|
2024
Q2 | $187M | Hold |
8,707,165
| – | – | 14.25% | 1 |
|
|
2024
Q1 | $162M | Hold |
8,707,165
| – | – | 12.01% | 3 |
|
|
2023
Q4 | $141M | Buy |
8,707,165
+927,165
| +12% | +$11.8M | 13.89% | 2 |
|
|
2023
Q3 | $107M | Buy |
7,780,000
+58,465
| +0.8% | +$921K | 11.89% | 2 |
|
|
2023
Q2 | $171M | Buy |
7,721,535
+150,000
| +2% | +$3.16M | 14.91% | 1 |
|
|
2023
Q1 | $165M | Buy |
7,571,535
+5,243
| +0.1% | +$118K | 13.57% | 1 |
|
|
2022
Q4 | $138M | Hold |
7,566,292
| – | – | 10.67% | 2 |
|
|
2022
Q3 | $172M | Hold |
7,566,292
| – | – | 11.31% | 2 |
|
|
2022
Q2 | $104M | Hold |
7,566,292
| – | – | 8.83% | 3 |
|
|
2022
Q1 | $172M | Hold |
7,566,292
| – | – | 7.71% | 1 |
|
|
2021
Q4 | $282M | Hold |
7,566,292
| – | – | 7.95% | 1 |
|
|
2021
Q3 | $320M | Buy |
7,566,292
+126,185
| +2% | +$6.08M | 7.97% | 2 |
|
|
2021
Q2 | $331M | Hold |
7,440,107
| – | – | 8.41% | 2 |
|
|
2021
Q1 | $268M | Hold |
7,440,107
| – | – | 7.98% | 4 |
|
|
2020
Q4 | $297M | Buy |
7,440,107
+1,600,000
| +27% | +$54.6M | 8.79% | 2 |
|
|
2020
Q3 | $169M | Buy |
5,840,107
+990,583
| +20% | +$21.4M | 7.57% | 2 |
|
|
2020
Q2 | $79.3M | Buy |
4,849,524
+2,380,953
| +96% | +$32.8M | 4.69% | 7 |
|
|
2020
Q1 | $23.5M | Hold |
2,468,571
| – | – | 2.49% | 16 |
|
|
2019
Q4 | $39.9M | Buy |
2,468,571
+40,000
| +2% | +$650K | 3.67% | 12 |
|
|
2019
Q3 | $40.4M | Hold |
2,428,571
| – | – | 4.18% | 10 |
|
|
2019
Q2 | $39.4M | Hold |
2,428,571
| – | – | 3.69% | 12 |
|
|
2019
Q1 | $43.4M | Hold |
2,428,571
| – | – | 4.77% | 9 |
|
|
2018
Q4 | $29.2M | Hold |
2,428,571
| – | – | 5% | 9 |
|
|
2018
Q3 | $42.5M | Buy |
2,428,571
+1,428,571
| +143% | +$28.3M | 5.17% | 6 |
|
|
2018
Q2 | $11.4M | Buy |
+1,000,000
| New | +$9.1M | 1.6% | 21 |
|
Other funds holding BLFS
FAM
Casdin Capital's BLFS Position: Q2 2026 in Review
Casdin Capital reduced its BioLife Solutions (BLFS) stake by 22% in Q2 2026, selling an estimated $30.4M and leaving 4,655,000 shares worth $131M. The position accounts for 6.58% of the portfolio, ranked #4.
Casdin Capital first reported a position in BLFS in Q2 2018 and has held it in 33 quarters since. The position peaked at $331M in Q2 2021. 216 funds tracked by Wall St. Rank hold BLFS as of Q2 2026.
- Casdin Capital held 4,655,000 shares of BioLife Solutions worth $131M as of Q2 2026.
- Casdin Capital sold 1,302,165 BioLife Solutions shares in Q2 2026, an estimated $30.4M.
- BioLife Solutions made up 6.58% of Casdin Capital's portfolio in Q2 2026, its #4 holding.
- Casdin Capital first reported a position in BioLife Solutions in Q2 2018 and has held it in 33 quarters since.
- Casdin Capital's BioLife Solutions position peaked at $331M in Q2 2021.
- 216 funds tracked by Wall St. Rank held BioLife Solutions as of Q2 2026.
Based on Casdin Capital's 13F filing for Q2 2026, filed 14 Aug 2026.